Page 17 - Peter Loftus News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Provided by Dow Jones By Matt Grossman and Peter Loftus Strong sales growth from pharmaceuticals lifted Johnson & Johnson's revenue in the latest quarter, even as the coronavirus pandemic weighed on other parts of the company's business. As the health-products company nears the release of pivotal data from a final-stage study of its Covid-19 vaccine, Johnson & Johnson said the pandemic was continuing to drag down sales of its medical devices as people postponed elective procedures. But modest growth in consumer-health products also contributed to the sales boost...

By Jared S. Hopkins and Peter Loftus Changes by the federal government to speed up Covid-19 vaccinations will increase doses available but might not help strapped health departments and hospitals give more shots more quickly, public health and hospital officials said. U.S. health officials said Tuesday that states should expand vaccine eligibility to people 65 years and older as well as those with pre-existing health conditions, a large group that most states didn't expect to inoculate for weeks. The U.S. will also stop holding back second doses, reversing the strategy since...

Full membership of The Wall Street Journal is bundled with subscriptions to BizPremium, which also includes access to a weekly webinar with top SA stock market experts, an exclusive monthly update on the top performing BizNews Share portfolio, an interactive WhatsApp group and Alec Hogg’s daily Rational Perspective newsletter. All for just R105 (£4.99) a month – for more details click here.  Use Spotify? Access BizNews podcasts here. Use Apple Podcasts? Access BizNews podcasts here. Covid-19 Vaccines: What’s Coming and When? As countries and companies race to produce a safe and effe...

Provided by Dow Jones By Peter Loftus and Thomas M. Burton U.S. health regulators on Friday permitted use of Moderna Inc.'s Covid-19 vaccine, the second shot to get the green light to help end the deadliest pandemic in more than a century. The U.S. Food and Drug Administration's authorization of Moderna's vaccine in people ages 18 years and older comes a week after the agency authorized the first shot in the U.S., from Pfizer Inc. and its partner BioNTech SE. Testing of the vaccine found that it protected against developing Covid-19 and was safe, though so...

Moderna Shot Expected to Bolster U.S. Vaccine Efforts © Hans Pennink/Associated Press Health officials across the U.S. are counting on the arrival of a second Covid-19 vaccine to boost scarce supplies and sidestep logistical issues encountered by the first vaccine, which began distribution this week. The U.S. Food and Drug Administration may issue an emergency authorization for a vaccine from Moderna Inc. as early as Friday after an advisory panel recommended the agency approve its use. If authorized, Moderna’s vaccine will join a vaccine from Pfizer Inc. and BioNTech SE that received aut...